Spotlight On... Aussie IPO for breast cancer imaging player Volpara raises almost $8M; Hansen submits to FDA for robotic surgery in neurology; FDA clears startup's real-time catheter monitor; and more...

Volpara Health Technologies ($VHT) has raised A$10 million ($7.6 million) in an IPO that values it at about $61 million. The company markets a suite of breast imaging tools for personalized breast cancer screening based on objective measurements of volumetric breast density, compression and radiation dose. More than 9 million women in over 30 countries have been examined with its technology. Volpara will use the IPO funds to expand its sales team, increase marketing in the U.S. and Europe, launch new products and incorporate predictive analytics. "To list on the ASX is a significant milestone which enables Volpara to accelerate its growth globally, as well as expand its ability to apply industry-leading digital health solutions to support the paradigm shift to personalized breast cancer screening that is being driven by women demanding better information, better screening systems, better healthcare and better results," said Volpara CEO Ralph Highnam in a statement. More

@FierceMedDev: JAMA: Adding 3-D mammography decreases patient recalls, increases cancer detection. More | Follow @FierceMedDev

@EmilyWFierce: Teva enlists House M.D. actress to amp up migraine awareness. FiercePharmaMarketing story | Follow @EmilyWFierce

@amirahalidrus Transatlantic team reverses Alzheimer's, Parkinson's symptoms in fruit flies. FierceBiotechResearch story | Follow @amirahalidrus

> Robotic surgery micro-cap Hansen Medical ($HNSN), which is slated to be acquired for $80 million by Auris Surgical Robotics, has submitted a 510(k) filing to FDA for neurological use of its Magellan Robotic System that would enable a peripheral vascular and neurological procedure indication. More

> Stryker ($SYK) has filed in New Jersey federal court suing DJO Global over raiding its employees in order to steal trade secrets and relationships, the company alleges. More

> The FDA has cleared a catheter monitoring system that's designed to monitor urine output, temperature and intra-abdominal pressure in real time in order to detect patients at risk of sepsis and acute kidney injury from startup Potrero Medical. More

Suggested Articles

BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.